Phosphodiesterase Type 5 Inhibitors as Adjunctive Therapy in the Management of Systolic Heart Failure;Inhibidores de la Fosfodiesterasa tipo 5 Como Tratamiento Adjunto en el Manejo de Fallo Cardiaco Sistólico

Annals of Pharmacotherapy

Volumn 45, Issue 12, 2011, Pages 1551-1558

  Cvelich, Ramonna G ^a   Roberts, Sarah C ^b   Brown, Jamie N ^a  

^a DURHAM VA MEDICAL CENTER   (United States)

^b CAMPBELL UNIVERSITY   (United States)

Author keywords

Exercise; Heart failure; Phosphodiesterase 5 inhibitor; Sildenafil; Tadalafil; Vardenafil

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; SPIRONOLACTONE; TADALAFIL; VARDENAFIL;

CARDIOVASCULAR FUNCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; FLUSHING; HEART ATRIUM FIBRILLATION; HEART RIGHT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LEG PAIN; LUNG ARTERY PRESSURE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTOLIC HEART FAILURE; THORAX PAIN;

CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONES;

EID: 83155182933     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q421     Document Type: Review

References (28)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
2. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-194.
3. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-209.
4. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45:968-74.
5. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 2003;160:719-27.
6. Lin CS, Lau A, Tu R, Lue TF. Expression of three isoforms of cGMPbinding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. Biochem Biophys Res Commun 2000;268:628-35.
7. Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375-414.
8. Williams BA, Liu C, Deyoung L, Brock GB, Sims SM. Regulation of intracellular Ca2+ release in corpus cavernosum smooth muscle: synergism between nitric oxide and cGMP. Am J Physiol Cell Physiol 2005;288:C650-8.
9. Movesian M, Stehilk J, Vandeput F, Bristow MR. Phosphodiesterase inhibition in heart failure. Heart Fail Rev 2009;14:255-63
10. Pérez NG, Piaggio MR, Ennis IL, et al. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 2007;49:1095-103.
11. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007;101:1084-95.
12. Guazzi M. Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail 2008;1:272-80.
13. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:689-702.
14. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007;116:1555-62.
15. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007;50:2136-44.
16. Behling A, Rohde LE, Colombo FC, Goldraich L, Stein R, Clausell N. Effects of 5E-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008;14:189-97.
17. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011;4:8-17.
18. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-51.
19. Bocchi EA, Guimarãs G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103.
20. Guazzi M, Tumminello G, Di Marco FD, Guazzi MD. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther 2004;76:371-8.
21. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilator efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004;44:2239-48.
22. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 2005;96:1436-40.
23. Hryniewicz K, Dimayuga C, Hudaihed A, et al. Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond) 2005;108:331-8.
24. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007;115:59-66.
25. Guazzi M, Casali M, Berti F, Rossoni G, Colonna VD, Guazzi MD. Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther 2008;83:336-41.
26. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164-74.
27. Cote C, Fotsch E, Tanzer D. Red book pharmacy's fundamental reference. Montvale, NJ: Thomson Reuters, 2010:711-804.
28. Product information. Viagra (sildenafil). New York: Pfizer Inc., January 2011.